Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Compassionate Use (CU) Program of Odronextamab

NCT05619367 is registered in ClinicalTrials.gov with Regeneron Pharmaceuticals as lead sponsor.

NCT NCT05619367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05619367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Compassionate Use (CU) Program of Odronextamab
Lead sponsor
Regeneron Pharmaceuticals
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non-hodgkin lymphoma (nhl), diffuse large b-cell lymphoma (dlbcl), high-grade b-cell lymphoma (hgbcl), relapsed or refractory (r/r) follicular lymphoma (fl)